Gemcitabine Plus Carboplatin Compared With Carboplatin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer: An Intergroup Trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG

Pfisterer, Jacobus; Plante, Marie; Vergote, Ignace; du Bois, Andreas; W. Hirte, Hal; J. Lacave, Ángel; Wagner, Uwe; Stähle, Anne; Stuart, Gavin; Kimmig, Rainer; Olbricht, S.; Le, Tien; Emerich, Janusz; Kuhn, Walther; Bentley, J.; Jackisch, Christian; Lück, Hans‐Joachim; Rochon, Justine; H. Zimmermann, Annamaria; A. Eisenhauer, Elizabeth

doi:10.1200/jco.2006.06.0913

Public

Gemcitabine Plus Carboplatin Compared With Carboplatin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer: An Intergroup Trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG

Published in Journal of Clinical Oncology • Sep 12, 2006

Authors:

Jacobus Pfisterer

Marie Plante

Ignace Vergote

Abstract

PURPOSE: Most patients with advanced ovarian cancer develop recurrent disease. For those patients who recur at least 6 months after initial therapy, paclitaxel platinum has shown a modest survival advantage over platinum without paclitaxel; however, many patients develop clinically relevant neurotox...

Subject

Carboplatin

Medicine

Gemcitabine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!